Patient reported quality of life in young adults with sarcoma receiving care at a sarcoma center.

Autor:	Day JR; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States., Miller B; Department of Orthopedics, Carver College of Medicine, University of Iowa, Iowa City, IA, United States., Loeffler BT; Holden Comprehensive Cancer Center, Iowa City, IA, United States., Mott SL; Holden Comprehensive Cancer Center, Iowa City, IA, United States., Tanas M; Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, United States., Curry M; Holden Comprehensive Cancer Center, Iowa City, IA, United States., Davick J; Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, United States., Milhem M; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States., Monga V; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychology [Front Psychol] 2022 Sep 29; Vol. 13, pp. 871254. Date of Electronic Publication: 2022 Sep 29 (Print Publication: 2022).
DOI:	10.3389/fpsyg.2022.871254
Abstrakt:	Background: Sarcomas are a diverse group of neoplasms that vary greatly in clinical presentation and responsiveness to treatment. Given the differences in the sites of involvement, rarity, and treatment modality, a multidisciplinary approach is required. Previous literature suggests patients with sarcoma suffer from poorer quality of life (QoL) especially physical and functional wellbeing. Adolescent and young adult (AYA) patients are an underrepresented population in cancer research and have differing factors influencing QoL. Methods: Retrospective analysis of Young Adult patients (age 18-39) enrolled in the Sarcoma Tissue Repository at University of Iowa. QoL was assessed using the self-report FACT-G questionnaire at enrollment and 12 months post-diagnosis; overall scores and the 4 wellbeing subscales (Physical, Emotional, Social, Functional) were calculated. Linear mixed effects models were used to measure the association between the rate of change in FACT-G subscale scores and baseline clinical, comorbidity, and treatment characteristics. Results: 49 patients were identified. 57.1% of patients had a malignancy involving an extremity. Mean FACT-G scores of overall wellbeing improved from baseline to 12 months (76.4 vs. 85.4, p < 0.01). Social and emotional wellbeing did not differ significantly between baseline and 12 months. Physical wellbeing (18.8 vs. 23.9, p < 0.01) and functional wellbeing (16.8 vs. 20.0, p < 0.01) scores improved from baseline to 12 months. No difference was seen for FACT-G overall scores for age, sex, laterality, marital status, performance status, having children, clinical stage, limb surgery, chemotherapy, or tumor size. A difference was demonstrated in physical wellbeing scores for patients with baseline limitation (ECOG 1-3) compared to those with no baseline limitation (ECOG 0) ( p = 0.03). A difference was demonstrated in social wellbeing based on anatomical site ( p = 0.02). Conclusion: Young adults with sarcoma treated at a tertiary center had improvements in overall reported QoL at 12 months from diagnosis. Overall baseline QoL scores on FACT-G were lower than the general adult population for YA patients with sarcoma but at 12 months became in line with general population norms. The improvements seen merit further investigation to evaluate how these change over the continuum of care. Quality of life changes may be useful outcomes of interest in sarcoma trials. Competing Interests: VM received research funding from Gateway Foundation, Rising Tide Cancer Research Foundation, Amgen. Advisory Board—Forma Therapeutics and Astex Pharmaceuticals. MM reports consultancy/advisory board for Blueprints Medicine, Immunocore, Amgen, Trieza, Array Biopharma, Biontech, and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Day, Miller, Loeffler, Mott, Tanas, Curry, Davick, Milhem and Monga.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu